Related Experiment Video
Updated: Aug 8, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Insights
Rapid human immunodeficiency virus (HIV) tests provide results in 20 minutes, improving clinical utility for pregnant women and high-risk individuals. Different rapid HIV tests are best for laboratory versus point-of-care settings.
Area of Science:
- Medical Diagnostics
- Infectious Disease Research
- Public Health
Background:
- Conventional human immunodeficiency virus (HIV) testing requires hours to weeks for results, limiting clinical usefulness.
- Rapid HIV tests offer results in 20 minutes or less, addressing the need for timely diagnosis.
- Timely HIV status information is crucial for preventing vertical transmission and guiding post-exposure prophylaxis.
Purpose of the Study:
- To evaluate three rapid HIV tests available in the United States.
- To assess the performance of rapid HIV tests for both laboratory use and point-of-care testing (POCT).
- To identify the top-rated rapid HIV test for distinct applications.
Main Methods:
- Evaluation of three specific rapid HIV test kits: MedMira Labs Reveal G2, OraSure Technologies OraQuick Advance, and Trinity Biotech Uni-Gold Recombigen HIV.
- Separate assessment of kits for laboratory applications, focusing on efficiency and workflow integration.
- Separate assessment of kits for POCT, prioritizing ease of use.
Main Results:
- The evaluation identified distinct top-performing rapid HIV tests for laboratory use and for POCT.
- Efficiency and workflow suitability were key factors for laboratory test selection.
- Ease of use was paramount for selecting a point-of-care testing (POCT) rapid HIV test.
Conclusions:
- Rapid HIV tests significantly improve the speed of diagnosis compared to conventional methods.
- The optimal rapid HIV test varies depending on whether it is used in a laboratory or a point-of-care setting.
- These evaluations guide the selection of appropriate rapid HIV tests to enhance HIV screening and management.
Abstract:
Conventional testing for human immunodeficiency virus (HIV)--the causative agent for acquired immunodeficiency syndrome (AIDS)--is an efficient way to screen large numbers of samples at one time. But initial results are often not available for hours or days; moreover, results are typically not released until confirmed, which can be weeks later. Consequently, conventional testing doesn't always provide information on HIV status quickly enough to be clinically useful. This limitation has led to the development of rapid HIV test kits, which can provide results in 20 minutes or less. Rapid HIV tests can be used for testing pregnant women in labor whose HIV status is unknown (to reduce vertical transmission from mother to fetus or infant) and for testing source individuals after occupational exposures (to help with drug treatment decisions). Additionally, the use of rapid test kits for screening high-risk individuals (especially those who may not return for results) is expected to increase the number of individuals who know their HIV status. This Evaluation looks at three rapid HIV tests currently available in the United States: the MedMira Labs Reveal G2 Rapid HIV-1 Antibody Test Kit, the OraSure Technologies OraQuick Advance Rapid HIV-1/2 Antibody Test, and the Trinity Biotech Uni-Gold Recombigen HIV. We rate the kits separately for laboratory use and for point-of-care testing (POCT). For laboratory applications, efficiency and suitability for the lab's workflow are the key selection factors. For POCT, ease of use is paramount. A different product was our top choice for each of these applications.
More Related Videos
07:40Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
Published on: June 29, 2020
13:58Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011